Lexaria Bioscience Corp.

US$4.50As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LEXXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (28.95%)
Div yield —
ROE (162.77%)
Biotechnology
Beta (5Y) 0.58
PE TTM —
TSR TTM (70.59%)
Mkt cap US$9.479M
ROIC (96.43%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$5.78
28.45%
(49.53%)
Hold 11|4|1|8|12
1Q26
2Q26
3Q26
4Q26
Earnings per share$
0.05
0.05
0.06
0.05
3.68%
10.72%
7.05%
3.16%
Revenue$M
0.802
0.806
0.828
0.843
3.94%
4.33%
9.99%
5.72%
Peers (US$9.479M)
Cap (US$)
PE
9.614M
—
9.467M
—
Capital
TTM
5Y
10Y
Leveragex
0.137
(0.503)
(0.362)
EBIT/Intx
0.935
0.222
0.226
Own earn%
(6.64)
43.50
39.54
Sh yield%
32.23
42.63
45.72
Owners
Insiders/Inst%
1.01
37.71
Short interest%
1.05
SBC / revenue%
0.42
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
15–22
$1 testx
—
Incr. ROIC%
6